Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Kenya: Hospitals Risk Social Health Authority Lockout As Contracts

[Capital FM] Nairobi -- Healthcare providers across the country risk being locked out of the Social Health Authority (SHA) system from Thursday if they fail to complete the contracting process for the new 2026-2029 cycle.

Hospitals and healthcare facilities in Kenya face potential termination from the Social Health Authority (SHA) system starting October 1, 2026, if they fail to finalize contracts for the upcoming 2026-2029 cycle. SHA CEO Dr. Mercy Mwangangi announced that existing contracts will expire on September 30, 2026, and providers without new contracts will be barred from accessing the SHA provider portal and providing services to SHA beneficiaries.

The authority emphasized the urgency for providers to apply for and complete the contracting process before the October 1 deadline. Failure to secure new contracts could disrupt treatment for patients reliant on these facilities, particularly those undergoing ongoing treatment or requiring regular procedures. SHA initiated the contracting process under the new electronic platform "HAKIKA" to enhance contracting, verification, payment, and accountability among providers.

Written by urgent.news from AllAfrica Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Read the original at allafrica.com →

More in Health & Medicine

Kenya: US Delegation Backs Fight Against Period Poverty in Kenyan Schools

[Capital FM] Kisii -- A delegation of US-based leaders and humanitarian advocates is in Kenya for a week-long outreach programme aimed at tackling period poverty among schoolgirls and promoting…

  • US delegation combats period poverty in Kenyan schools
  • Provides sanitary products, menstrual hygiene education
  • Focuses on restoring dignity, ensuring school attendance

Innovent Biologics expands Phase 3 lung cancer trial globally

Biopharmaceutical manufacturer Innovent Biologics expanded its global Phase 3 MarsLight 11 clinical trial of candidate IBI363 TAK 928 to evaluate patients with immunotherapy resistant non squamous non…

  • Innovent Biologics expands MarsLight-11 Phase 3 lung cancer trial globally.
  • Trial now includes non-squamous non-small cell lung cancer patients.
  • IBI363/TAK-928 bispecific fusion protein assessed against docetaxel.

XtalPi files FDA application for intestinal pain drug candidate

Technology firm XtalPi submitted an Investigational New Drug application to the US Food and Drug Administration to initiate clinical trials for its gut restricted inhibitor KQTD 126

  • XtalPi submits FDA IND application for KQTD-126 intestinal pain drug.
  • KQTD-126 targets TRK family receptors to manage chronic intestinal pain.
  • Preclinical studies show pan-TRK inhibition at sub-nanomolar concentrations.

More from Monday 28 September →